Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation

W. N. Charman, S. A. Charman, D. C. Monkhouse, S. E. Frisbee, E. A. Lockhart, S. Weisman, G. A. Fitzgerald

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The release of aspirin from a 75 mg controlled-release formulation, designed to inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin biosynthesis, was characterised in healthy subjects. The calculated in vivo release rate of aspirin matched the design goal of approximately 10 mg h-1. The C(max) of aspirin associated with the controlled-release formulation was lowered 15-fold relative to a solution formulation of the same dose. The bioavailability of aspirin (based on salicylate concentrations) from the controlled-release formulation was approximately 90% relative to the solution, and drug release was not affected by co-administration of a standard breakfast.

Original languageEnglish
Pages (from-to)470-473
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume36
Issue number5
Publication statusPublished - 1993
Externally publishedYes

Keywords

  • cardiovascular
  • controlled-release
  • food effect
  • low-dose aspirin

Cite this

Charman, W. N., Charman, S. A., Monkhouse, D. C., Frisbee, S. E., Lockhart, E. A., Weisman, S., & Fitzgerald, G. A. (1993). Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. British Journal of Clinical Pharmacology, 36(5), 470-473.
Charman, W. N. ; Charman, S. A. ; Monkhouse, D. C. ; Frisbee, S. E. ; Lockhart, E. A. ; Weisman, S. ; Fitzgerald, G. A. / Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. In: British Journal of Clinical Pharmacology. 1993 ; Vol. 36, No. 5. pp. 470-473.
@article{21463c51393c4ed981921964dad3e8f0,
title = "Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation",
abstract = "The release of aspirin from a 75 mg controlled-release formulation, designed to inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin biosynthesis, was characterised in healthy subjects. The calculated in vivo release rate of aspirin matched the design goal of approximately 10 mg h-1. The C(max) of aspirin associated with the controlled-release formulation was lowered 15-fold relative to a solution formulation of the same dose. The bioavailability of aspirin (based on salicylate concentrations) from the controlled-release formulation was approximately 90{\%} relative to the solution, and drug release was not affected by co-administration of a standard breakfast.",
keywords = "cardiovascular, controlled-release, food effect, low-dose aspirin",
author = "Charman, {W. N.} and Charman, {S. A.} and Monkhouse, {D. C.} and Frisbee, {S. E.} and Lockhart, {E. A.} and S. Weisman and Fitzgerald, {G. A.}",
year = "1993",
language = "English",
volume = "36",
pages = "470--473",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",
number = "5",

}

Charman, WN, Charman, SA, Monkhouse, DC, Frisbee, SE, Lockhart, EA, Weisman, S & Fitzgerald, GA 1993, 'Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation' British Journal of Clinical Pharmacology, vol. 36, no. 5, pp. 470-473.

Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. / Charman, W. N.; Charman, S. A.; Monkhouse, D. C.; Frisbee, S. E.; Lockhart, E. A.; Weisman, S.; Fitzgerald, G. A.

In: British Journal of Clinical Pharmacology, Vol. 36, No. 5, 1993, p. 470-473.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation

AU - Charman, W. N.

AU - Charman, S. A.

AU - Monkhouse, D. C.

AU - Frisbee, S. E.

AU - Lockhart, E. A.

AU - Weisman, S.

AU - Fitzgerald, G. A.

PY - 1993

Y1 - 1993

N2 - The release of aspirin from a 75 mg controlled-release formulation, designed to inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin biosynthesis, was characterised in healthy subjects. The calculated in vivo release rate of aspirin matched the design goal of approximately 10 mg h-1. The C(max) of aspirin associated with the controlled-release formulation was lowered 15-fold relative to a solution formulation of the same dose. The bioavailability of aspirin (based on salicylate concentrations) from the controlled-release formulation was approximately 90% relative to the solution, and drug release was not affected by co-administration of a standard breakfast.

AB - The release of aspirin from a 75 mg controlled-release formulation, designed to inhibit maximally thromboxane A2 production while sparing stimulated prostacyclin biosynthesis, was characterised in healthy subjects. The calculated in vivo release rate of aspirin matched the design goal of approximately 10 mg h-1. The C(max) of aspirin associated with the controlled-release formulation was lowered 15-fold relative to a solution formulation of the same dose. The bioavailability of aspirin (based on salicylate concentrations) from the controlled-release formulation was approximately 90% relative to the solution, and drug release was not affected by co-administration of a standard breakfast.

KW - cardiovascular

KW - controlled-release

KW - food effect

KW - low-dose aspirin

UR - http://www.scopus.com/inward/record.url?scp=0027420534&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 470

EP - 473

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 5

ER -